Jean Gariepy

Jean Gariepy

University of Toronto

H-index: 49

North America-Canada

About Jean Gariepy

Jean Gariepy, With an exceptional h-index of 49 and a recent h-index of 23 (since 2020), a distinguished researcher at University of Toronto, specializes in the field of Biotherapeutics, cancer, cancer therapy, immunotherapy, inflammatory diseases.

His recent articles reflect a diverse array of research interests and contributions to the field:

A novel immunotherapy for metastatic prostate cancer: A monoclonal antibody that can bind both STEAP1 and STEAP2

Devices and methods for wound-conformal guidance of bioprinter printhead

Emerging insights into ethnic-specific TP53 germline variants

Bispecific constructs for expanding t cells and related methods

VEGF-B prevents excessive angiogenesis by inhibiting FGF2/FGFR1 pathway

The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity

VISTA as a ligand downregulates LPS-mediated inflammation in macrophages and neutrophils

Can CD200R1 agonists slow the progression of osteoarthritis secondary to injury?

Jean Gariepy Information

University

Position

Professor of Medical Biophysics

Citations(all)

7426

Citations(since 2020)

1488

Cited By

6635

hIndex(all)

49

hIndex(since 2020)

23

i10Index(all)

99

i10Index(since 2020)

43

Email

University Profile Page

Google Scholar

Jean Gariepy Skills & Research Interests

Biotherapeutics

cancer

cancer therapy

immunotherapy

inflammatory diseases

Top articles of Jean Gariepy

A novel immunotherapy for metastatic prostate cancer: A monoclonal antibody that can bind both STEAP1 and STEAP2

Cancer Research

2024/3/22

Devices and methods for wound-conformal guidance of bioprinter printhead

2024/2/27

Emerging insights into ethnic-specific TP53 germline variants

2023/10/1

Bispecific constructs for expanding t cells and related methods

2023/8/23

The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity

Scientific Reports

2023/3/21

VISTA as a ligand downregulates LPS-mediated inflammation in macrophages and neutrophils

Cellular Immunology

2022/9/1

Can CD200R1 agonists slow the progression of osteoarthritis secondary to injury?

Frontiers in Immunology

2022/3/14

Engineered t-cell modulating molecules and methods of using same

2022/2/10

Labeling Cell Surface Receptors with Ligand. BirA* Bispecifics

ACS Pharmacology & Translational Science

2022/2/1

Agonistic nanobodies and antibodies to human VISTA

mAbs

2021/1/1

A soluble activator that favors the ex vivo expansion of CD8+ CD27+ T cells

JCI insight

2020/11/11

TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard …

Cancers

2020/7/24

Glypican-6 stimulates intestinal elongation by simultaneously regulating Hedgehog and non-canonical Wnt signaling

Matrix Biology

2020/6/1

Enhancing checkpoint inhibitor therapy with ultrasound stimulated microbubbles.

2020/4/1

Jean Gariepy
Jean Gariepy

H-Index: 19

Kullervo Hynynen
Kullervo Hynynen

H-Index: 67

Abstract A20: Enhancing checkpoint inhibitor therapy with ultrasound stimulated microbubbles

Cancer Immunology Research

2020/4/1

Jean Gariepy
Jean Gariepy

H-Index: 19

Kullervo Hynynen
Kullervo Hynynen

H-Index: 67

DNA aptamers specific to CD2000R1 and their therapeutic uses

2020/3/10

Coupling Chlorin e6 to the surface of Nanoscale Gas Vesicles strongly enhances their intracellular delivery and photodynamic killing of cancer cells

Scientific Reports

2020/2/18

Handheld instrument for wound-conformal delivery of skin precursor sheets improves healing in full-thickness burns

Biofabrication

2020/2/4

Author Correction: Coupling Chlorin e6 to the surface of Nanoscale Gas Vesicles strongly enhances their intracellular delivery and photodynamic killing of cancer cells

Scientific Reports

2020

See List of Professors in Jean Gariepy University(University of Toronto)